Patent · US Expired

Method for androgen supplementation

US5342834A · kind A · utility

8Cited by
3References
6Claims
0Family size

Assignee

Inventors

Key dates

Filing dateOct 15, 1992
Grant dateAug 30, 1994
Priority date
Expiry dateOct 15, 2012

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K31/565
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

A particular group of androgens is not metabolized to their 5.alpha.-reduced form in the prostate and other tissues. Thus, administration of these compounds--testosterone derivatives with a non-hydrogen substituent in the 6.alpha. or 7.alpha. position--allows one to provide androgen supplementation therapy without stimulating abnormal prostate growth. A preferred compound for use in the invention is 7.alpha.-methyl-19-nortestosterone.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.